Transcatheter Tricuspid Valve Implantation of NaviGate Bioprosthesis in a Preclinical Model.

•Surgery for isolated tricuspid regurgitation carries a high mortality risk, especially in the setting of right ventricular dysfunction and reoperation.•Transcatheter valve therapy is as promising alternative for treatment of isolated tricuspid valve disease associated with right heart failure.•The NaviGate bioprosthesis is a novel self-expanding valved stent designed to treat functional tricuspid regurgitation.•The preclinical evaluation shows that transcatheter tricuspid valve implantation using the NaviGate device is safe, is feasible through 2 different approaches, and results in a secure and stable engagement of the native annulus, with excellent hemodynamic and valve performance.